DYN
Dyne Therapeutics, Inc.- Healthcare
- Biotechnology
- $3.40B market cap
Forecast run · Sep 14, 2026Upside rank 1179 of 3,136
Model Signal
ForecastQ Daily Probabilities
41.6%
51.4%
26.7%
Analyst Consensus
Recommendation2.14/5 Buy
Last price$18.21
Price target$33.71
Implied move+85.1%
Analysts14
ForecastQ Portfolios
DYN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.